Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics
GRCL Price/Volume Stats
| Current price | $3.08 | 52-week high | $5.69 |
| Prev. close | $2.98 | 52-week low | $1.40 |
| Day low | $2.88 | Volume | 80,640 |
| Day high | $3.09 | Avg. volume | 269,267 |
| 50-day MA | $2.08 | Dividend yield | N/A |
| 200-day MA | $2.48 | Market Cap | 208.56M |
GRCL Stock Price Chart Interactive Chart >
Gracell Biotechnologies Inc. (GRCL) Company Bio
Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.
Latest GRCL News From Around the Web
Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.
Q1 2023 Gracell Biotechnologies Inc Earnings CallQ1 2023 Gracell Biotechnologies Inc Earnings Call |
Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22ndSAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced that it will host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am ET. Gracell Biotechnologies’ KOL event will feature participation from management and key |
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer and autoimmune diseases, today announced the initiation of an investigator-initiated trial (IIT) in China of GC012F, the Company's autologous FasTCAR therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, for the treatment of refractory SLE. |
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate UpdatePresenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and EHA2023On track to commence a Phase 1b/2 clinical trial in U.S. and a Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the second quarter and third quarter of 2023, respectivelyLaunched the new IIT evaluating GC012F in systemic lupus erythematosus (SLE)Presenting updated d |
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 CongressGracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online. Clinical data from GC012F, the Company's FasTCAR-enable |
GRCL Price Returns
| 1-mo | 57.95% |
| 3-mo | 52.48% |
| 6-mo | -6.67% |
| 1-year | 12.82% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 33.91% |
| 2022 | -61.92% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...